The invention provides a silica nanoparticle comprising a non-porous matrix of silicon-oxygen bonds, wherein the matrix comprises organic agents conjugated to...
The invention provides a silica nanoparticle comprising a non-porous matrix of silicon-oxygen bonds, wherein the matrix comprises organic agents conjugated to silicon or oxygen atoms in the matrix, the organic agents are conjugated to the matrix through linker L groups, wherein the linker L comprises, for example, an ester, urea, thiourea, or thio ether group, and wherein the diameter of the nanoparticle is about 15 nm to about 200 nm. The invention also provides novel methods of making and using the silica nanoparticles.
A system that incorporates teachings of the present disclosure may include, for example, an apparatus having an outer nozzle operable to discharge an outer stream...
A system that incorporates teachings of the present disclosure may include, for example, an apparatus having an outer nozzle operable to discharge an outer stream of a shell solution, and an inner nozzle operable to discharge an inner stream of a core solution intermixed with a plurality of materials. The outer stream can substantially surrounds the inner stream, thereby forming a combined stream. A plurality of capsules can be formed responsive to a force applied to the combined stream. At least a portion of the plurality of capsules are desirable capsules, each having a core encapsulated by a portion of the shell solution. The core can have at least one of the plurality of materials encapsulated by a portion of the core solution without protruding an outer surface of the portion of the shell solution.
An amphiphilic substance includes a hydrophobic group, and a polynucleotide group attached to the hydrophobic group. The polynucleotide group includes a first...
An amphiphilic substance includes a hydrophobic group, and a polynucleotide group attached to the hydrophobic group. The polynucleotide group includes a first polynucleotide segment and a second polynucleotide segment. The first and second polynucleotide segments are at least partially complementary and are bound together by interactions including base pairing. At least one of the first and second segments includes at least one of an aptamer and a nucleic acid-based enzyme. A lipid vesicle may include the amphiphilic substance, a first polar lipid that is an unstable vesicle former, and a polar liquid. Upon exposure to a rupture agent, the vesicle may rupture, releasing the contents of the vesicle. Substances that may be released from the vesicle include bioactive agents, such as drug agents.
This technology is a viral vector based on the murine leukemia virus (MLV), which has been favored for clinical gene therapy due to its preferential infectivity of...
This technology is a viral vector based on the murine leukemia virus (MLV), which has been favored for clinical gene therapy due to its preferential infectivity of human cell types. The original vector has been modified through the use of directed evolution targeting its protease (PR) gene, which has been found to produce increased stability for the viral vector. It is believed that this modification has the potential to be applied to all clinically-relevant viral vectors.
Applications
Clinical, such as delivery of gene therapy therapeutics
Biomedical Research by way of development of gene therapy therapeutics and general basic science research.
Benefits
Increased virus production.
Increased infection efficiency.
Increased safety (indirect benefit of decrease in required vector dose).
